Skip to main content
Erschienen in: Infection 3/2022

04.01.2022 | COVID-19 | Original Paper Zur Zeit gratis

COVID-19: vaccination vs. hospitalization

verfasst von: Oguz Uzun, Tekin Akpolat, Ayhan Varol, Sema Turan, Serife Gokbulut Bektas, Pelin Duru Cetinkaya, Mazlum Dursun, Nurten Bakan, Burcu Baran Ketencioglu, Murat Bayrak, Serap Argun Baris, Rahmet Guner, Ozgur Gunal, Serkan Nural, Pelin Pinar Deniz, Oya Baydar Toprak, Gulcihan Ozkan, Ayça Gumus, Ferhan Kerget, Merve Ercelik, Ozlem Ataoglu, Aycan Yuksel, Gungor Ates, Oya Eren Kutsoylu, Neslihan Kose, Deniz Kizilirmak, Serdar Keskin, Okkes Gultekin, Nilüfer Coskun, Emine Serap Yilmaz, Selen Uslu, İlknur Basyigit, Begüm Ergan, Figen Deveci, Mehmet Nuri Yakar, Cigdem Zuhur, Gulseren Sagcan, Zeynep Ture Yuce, Mutlu Kuluozturk, Mehmet Emin Sezgin, Esma Nur Aktepe Sezgin, Yavuz Havlucu, Caglar Cuhadaroglu, Oguz Kilinc, Hasim Boyaci, Hayriye Altunay, Mehmet Akti, Zehra Bastepe Dursun, Ayse Kaya Kalem, Sinem Akkaya Isik, Levent Akyildiz, Nilüfer Aykac, Mehmet Selim Almaz, Nurdan Kokturk, Oya Itil

Erschienen in: Infection | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Objective

Vaccination is the most efficient way to control the coronavirus disease 2019 (COVID-19) pandemic, but vaccination rates remain below the target level in most countries. This multicenter study aimed to evaluate the vaccination status of hospitalized patients and compare two different booster vaccine protocols.

Setting

Inoculation in Turkey began in mid-January 2021. Sinovac was the only available vaccine until April 2021, when BioNTech was added. At the beginning of July 2021, the government offered a third booster dose to healthcare workers and people aged > 50 years who had received the two doses of Sinovac. Of the participants who received a booster, most chose BioNTech as the third dose.

Methods

We collected data from 25 hospitals in 16 cities. Patients hospitalized between August 1 and 10, 2021, were included and categorized into eight groups according to their vaccination status.

Results

We identified 1401 patients, of which 529 (37.7%) were admitted to intensive care units. Nearly half (47.8%) of the patients were not vaccinated, and those with two doses of Sinovac formed the second largest group (32.9%). Hospitalizations were lower in the group which received 2 doses of Sinovac and a booster dose of BioNTech than in the group which received 3 doses of Sinovac.

Conclusion

Effective vaccinations decreased COVID-19-related hospitalizations. The efficacy after two doses of Sinovac may decrease over time; however, it may be enhanced by adding a booster dose. Moreover, unvaccinated patients may be persuaded to undergo vaccination.
Literatur
5.
Zurück zum Zitat Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15.CrossRef Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15.CrossRef
6.
Zurück zum Zitat Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–81.CrossRef Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–81.CrossRef
7.
Zurück zum Zitat Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819–29.CrossRef Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819–29.CrossRef
9.
Zurück zum Zitat Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213–22.CrossRef Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213–22.CrossRef
12.
Zurück zum Zitat Akpolat T, Uzun O. Reduced mortality rate after coronavac vaccine among healthcare workers. J Infect. 2021;83:e20–1.CrossRef Akpolat T, Uzun O. Reduced mortality rate after coronavac vaccine among healthcare workers. J Infect. 2021;83:e20–1.CrossRef
Metadaten
Titel
COVID-19: vaccination vs. hospitalization
verfasst von
Oguz Uzun
Tekin Akpolat
Ayhan Varol
Sema Turan
Serife Gokbulut Bektas
Pelin Duru Cetinkaya
Mazlum Dursun
Nurten Bakan
Burcu Baran Ketencioglu
Murat Bayrak
Serap Argun Baris
Rahmet Guner
Ozgur Gunal
Serkan Nural
Pelin Pinar Deniz
Oya Baydar Toprak
Gulcihan Ozkan
Ayça Gumus
Ferhan Kerget
Merve Ercelik
Ozlem Ataoglu
Aycan Yuksel
Gungor Ates
Oya Eren Kutsoylu
Neslihan Kose
Deniz Kizilirmak
Serdar Keskin
Okkes Gultekin
Nilüfer Coskun
Emine Serap Yilmaz
Selen Uslu
İlknur Basyigit
Begüm Ergan
Figen Deveci
Mehmet Nuri Yakar
Cigdem Zuhur
Gulseren Sagcan
Zeynep Ture Yuce
Mutlu Kuluozturk
Mehmet Emin Sezgin
Esma Nur Aktepe Sezgin
Yavuz Havlucu
Caglar Cuhadaroglu
Oguz Kilinc
Hasim Boyaci
Hayriye Altunay
Mehmet Akti
Zehra Bastepe Dursun
Ayse Kaya Kalem
Sinem Akkaya Isik
Levent Akyildiz
Nilüfer Aykac
Mehmet Selim Almaz
Nurdan Kokturk
Oya Itil
Publikationsdatum
04.01.2022
Verlag
Springer Berlin Heidelberg
Schlagwort
COVID-19
Erschienen in
Infection / Ausgabe 3/2022
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-021-01751-1

Weitere Artikel der Ausgabe 3/2022

Infection 3/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.